Infliximab for the treatment of CNS sarcoidosis
A multi-institutional series
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To describe clinical and imaging responses in neurosarcoidosis to infliximab, a monoclonal antibody against tumor necrosis factor–α.
Methods: Investigators at 6 US centers retrospectively identified patients with CNS sarcoidosis treated with infliximab, including only patients with definite or probable neurosarcoidosis following rigorous exclusion of other causes.
Results: Of 66 patients with CNS sarcoidosis (27 definite, 39 probable) treated with infliximab for a median of 1.5 years, the mean age was 47.5 years at infliximab initiation (SD 11.7, range 24–71 years); 56.1% were female; 62.1% were white, 37.0% African American, and 3% Hispanic. Sarcoidosis was isolated to the CNS in 19.7%. Using infliximab doses ranging from 3 to 7 mg/kg every 4–8 weeks, MRI evidence of a favorable treatment response was observed in 82.1% of patients with imaging follow-up (n = 56), with complete remission of active disease in 51.8% and partial MRI improvement in 30.1%; MRI worsened in 1 patient (1.8%). There was clinical improvement in 77.3% of patients, with complete neurologic recovery in 28.8%, partial improvement in 48.5%, clinical stability in 18.2%, worsening in 3%, and 1 lost to follow-up. In 16 patients in remission when infliximab was discontinued, the disease recurred in 9 (56%), typically in the same neuroanatomic location.
Conclusions: Most patients with CNS sarcoidosis treated with infliximab exhibit favorable imaging and clinical treatment responses, including some previously refractory to other immunosuppressive treatments.
Classification of evidence: This study provides Class IV evidence that for patients with CNS sarcoidosis infliximab is associated with favorable imaging and clinical responses.
GLOSSARY
- CI=
- confidence interval;
- CVID=
- combined variable immunodeficiency;
- OR=
- odds ratio;
- TNF-α=
- tumor necrosis factor–α
Footnotes
↵* These authors contributed equally to this work and should be considered co–first authors.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Supplemental data at Neurology.org
- Received April 14, 2017.
- Accepted in final form August 30, 2017.
- © 2017 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Author response: Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series
- Michael J Bradshaw, Neuroimmunology/Autoimmune Neurology Fellow, Brigham and Women's Hospital; Massachusetts General Hospital; Harvard Medical School
- Jeffrey M Gelfand, Assistant Professor of Neurology, University of California, San Francisco
- Siddharama Pawate, Assistant Professor of Neurology, Vanderbilt University Medical Center
Submitted March 09, 2018 - Infliximab in neurosarcoidosis
- Jagannadha Avasarala, Associate Professor of Neurology, USC School of Medicine (Greenville, SC)[email protected]
Submitted December 04, 2017
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
NeurosarcoidosisLongitudinal experience in a single-center, academic healthcare systemJennifer Lord, M. Mateo Paz Soldan, Jonathan Galli et al.Neurology: Neuroimmunology & Neuroinflammation, May 13, 2020 -
Article
Infliximab treatment in pathology-confirmed neurosarcoidosisDaan Fritz, Wilhelmina M.C. Timmermans, Jan A.M. van Laar et al.Neurology: Neuroimmunology & Neuroinflammation, July 27, 2020 -
Article
Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysisA retrospective studyTarunya Arun, Laura Pattison, Jacqueline Palace et al.Neurology, April 30, 2020 -
Clinical and Ethical Challenges
Conjunctival biopsy to diagnose neurosarcoidosis in patients with inflammatory nervous system disease of unknown etiologyMichael R. Pichler, Eoin P. Flanagan, Allen J. Aksamit et al.Neurology: Clinical Practice, January 16, 2015